MedTrace Logo

Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis

NCT02371941 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-10-26

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled study of oral cromolyn sodium when made into a viscous preparation for the treatment of eosinophilic esophagitis.

Conditions

  • Eosinophilic Esophagitis

Interventions

DRUG

oral cromolyn sodium

Oral cromolyn sodium

DRUG

Placebo

Saline

Sponsors & Collaborators

  • University of Tennessee

    lead OTHER

Principal Investigators

  • Jay A Lieberman, MD · The University of Tennessee Health Science Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-07-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02371941 on ClinicalTrials.gov